Fluidigm

Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.

The consortium is developing a real-time PCR test for host detection assays targeting epigenetic signatures and viral RNA for early-stage monitoring of potentially infected individuals.

News items for the in vitro diagnostics industry for the week of March 2, 2020.

The International Panel Physicians Association has endorsed Qiagen's QuantiFeron-TB Gold Plus test for immigration medical screening for latent tuberculosis.

ioMérieux this week released consolidated financial statements for the year ended Dec. 31, 2017, confirming the earnings it reported in January.

Ascendas will develop and commercialize molecular diagnostic systems and assays using certain of Fluidigm's microfluidic technologies.